Literature DB >> 3153245

Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.

R Riccardi1, F M Balis, P Ferrara, A Lasorella, D G Poplack, R Mastrangelo.   

Abstract

Plasma levels of 6-mercaptopurine (6-MP) were measured after oral administration in 17 children with acute lymphoblastic leukemia (ALL). In the fasting state or after a breakfast consisting of 250 ml milk and 50 g biscuits, 6-MP was administered at a dose of 75 mg/m2. In patients studied in a fasting state, the mean time to plasma peak (tmax) level was 1.2 h, whereas in patient studied after breakfast the mean tmax was 2.3 h. This difference is statistically significant (p less than 0.001). Moreover, the 6-MP peak plasma concentration (cmax) and the areas under the plasma concentration time curves (AUC) were significantly reduced when the drug was administered after breakfast. The mean Cmax +/- SD were 0.98 +/- 0.54 microM and 0.63 +/- 0.48 microM, respectively (p less than 0.05). The mean 6-MP AUC +/- SD in patients studied in a fasting state and after breakfast were 143 +/- 69 microM min and 105 +/- 68 microM, respectively (p less than 0.01). These results indicated that 6-MP should be taken in a fasting state to optimize drug absorption in children undergoing chemotherapy for ALL.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3153245     DOI: 10.3109/08880018609031233

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  15 in total

Review 1.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy.

Authors:  Brahma N Singh; Bimal K Malhotra
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  Cranial irradiation and cerebrospinal fluid levels of 6-mercaptopurine in children with acute leukemia.

Authors:  R Riccardi; A Lasorella; R L Tartaglia; A Riccardi; T Servidei; R Mastrangelo
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

4.  Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1.

Authors:  Wendy Landier; Lindsey Hageman; Yanjun Chen; Nancy Kornegay; William E Evans; Bruce C Bostrom; Jacqueline Casillas; David S Dickens; Anne L Angiolillo; Glen Lew; Kelly W Maloney; Leo Mascarenhas; A Kim Ritchey; Amanda M Termuhlen; William L Carroll; Mary V Relling; F Lennie Wong; Smita Bhatia
Journal:  J Clin Oncol       Date:  2017-03-24       Impact factor: 44.544

Review 5.  Drug interactions in childhood cancer.

Authors:  Cyrine Haidar; Sima Jeha
Journal:  Lancet Oncol       Date:  2010-09-22       Impact factor: 41.316

6.  Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia.

Authors:  P Lafolie; O Björk; S Hayder; L Ahström; C Peterson
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

7.  6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations.

Authors:  D L Lancaster; N Patel; L Lennard; J S Lilleyman
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

8.  Rectal bioavailability of 6-mercaptopurine in children with acute lymphoblastic leukaemia: partial avoidance of "first-pass" metabolism.

Authors:  Y Kato; T Matsushita; H Uchida; S Egi; T Yokoyama; K Mohri
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

9.  Intraindividual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukaemia.

Authors:  P Lafolie; S Hayder; O Björk; C Peterson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate.

Authors:  F Innocenti; R Danesi; A Di Paolo; B Loru; C Favre; M Nardi; G Bocci; D Nardini; P Macchia; M Del Tacca
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.